Nectin Therapeutics Ltd
1 clinical trials · Sponsor
◉ Watch Nectin Therapeutics Ltd
| Record | Firm | Date |
|---|---|---|
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab (NCT05378425) | Nectin Therapeutics Ltd | 2022-09-01 |
Track Nectin Therapeutics Ltd automatically
Every clearance here is in the API, with alerts when new ones post.